An overview of mouse models of hepatocellular carcinoma.

IF 3.1 2区医学 Q3 IMMUNOLOGY

Infectious Agents and Cancer Pub Date : 2023-09-05 DOI:10.1186/s13027-023-00524-9

Hua-Chuan Zheng, Hang Xue, Wen-Jing Yun

引用次数: 0

Abstract

Hepatocellular carcinoma (HCC) has become a severe burden on global health due to its high morbidity and mortality rates. However, effective treatments for HCC are limited. The lack of suitable preclinical models may contribute to a major failure of drug development for HCC. Here, we overview several well-established mouse models of HCC, including genetically engineered mice, chemically-induced models, implantation models, and humanized mice. Immunotherapy studies of HCC have been a hot topic. Therefore, we will introduce the application of mouse models of HCC in immunotherapy. This is followed by a discussion of some other models of HCC-related liver diseases, including non-alcoholic fatty liver disease (NAFLD), hepatitis B and C virus infection, and liver fibrosis and cirrhosis. Together these provide researchers with a current overview of the mouse models of HCC and assist in the application of appropriate models for their research.

Abstract Image

查看原文本刊更多论文

肝细胞癌小鼠模型综述。

肝细胞癌(HCC)因其高发病率和死亡率已成为全球健康的严重负担。然而，HCC的有效治疗是有限的。缺乏合适的临床前模型可能导致HCC药物开发的主要失败。在这里，我们概述了几种成熟的小鼠肝癌模型，包括基因工程小鼠、化学诱导模型、植入模型和人源化小鼠。肝细胞癌的免疫治疗研究一直是一个热门话题。因此，我们将介绍小鼠肝癌模型在免疫治疗中的应用。随后讨论了hcc相关肝病的其他一些模型，包括非酒精性脂肪性肝病(NAFLD)、乙型和丙型肝炎病毒感染、肝纤维化和肝硬化。总之，这些为研究人员提供了HCC小鼠模型的当前概况，并协助他们应用适当的模型进行研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious Agents and Cancer ONCOLOGY-IMMUNOLOGY

CiteScore

5.80

自引率

2.70%

发文量

期刊介绍： Infectious Agents and Cancer is an open access, peer-reviewed online journal that encompasses all aspects of basic, clinical, epidemiological and translational research providing an insight into the association between chronic infections and cancer. The journal welcomes submissions in the pathogen-related cancer areas and other related topics, in particular: • HPV and anogenital cancers, as well as head and neck cancers; • EBV and Burkitt lymphoma; • HCV/HBV and hepatocellular carcinoma as well as lymphoproliferative diseases; • HHV8 and Kaposi sarcoma; • HTLV and leukemia; • Cancers in Low- and Middle-income countries. The link between infection and cancer has become well established over the past 50 years, and infection-associated cancer contribute up to 16% of cancers in developed countries and 33% in less developed countries. Preventive vaccines have been developed for only two cancer-causing viruses, highlighting both the opportunity to prevent infection-associated cancers by vaccination and the gaps that remain before vaccines can be developed for other cancer-causing agents. These gaps are due to incomplete understanding of the basic biology, natural history, epidemiology of many of the pathogens that cause cancer, the mechanisms they exploit to cause cancer, and how to interrupt progression to cancer in human populations. Early diagnosis or identification of lesions at high risk of progression represent the current most critical research area of the field supported by recent advances in genomics and proteomics technologies.